logo banner home news contact
nav

news

events

 

News

Return to News

Merix BIOSCIENCE LICENSED PATENT TO USE RNA LOADED CELLS TO TREAT CANCERS AND PATHOGEN INFECTIONS

DURHAM, NORTH CAROLINA, November 27, 2001 - Merix Bioscience, Inc. (Merix) announced today that a core patent has just been issued from the U.S. Patent and Trademark Office. This patent, which had previously been licensed on an exclusive worldwide basis from DUKE University, provides the company with substantially more options for treating cancer and infectious diseases. Using defined RNA antigens Merix can now target certain cancers and infectious diseases, such as Hepatitis C, with patient specific (autologous) dendritic cell vaccines.

“With our proprietary technologies we can potentially produce individualized vaccines to treat virtually any patient with any type of cancer or infectious disease,” said Mark Weedon, President and Chief Executive Officer. “In addition we are also exploring how these vaccines can be adapted to treat autoimmune and transplant related disorders as well.”

While there is general agreement among experts in the field that dendritic cells offer one of the most efficient means for eliciting an in vivo immune response, their clinical applications have been limited by the availability of disease specific antigens. Merix has addressed this issue by developing an RNA based method for transfecting dendritic cells using the full repertoire of antigens derived from the patient’s own cancer. In addition Merix can now produce RNA transcripts of defined antigens to certain cancers and infectious diseases thereby offering even greater flexibility to induce the most potent immune response possible.

About Merix
Merix Bioscience, Inc. is a private immunotherapy company poised to assume leadership in the large emerging market of cancer vaccines. The Company's proprietary platform technology encompasses methods to optimize the preparation of dendritic cells, methods for the antigen loading (transfection) of dendritic cells, and the application of the resulting vaccines in the treatment of cancer, chronic infectious diseases and immune disorders. Merix offers a unique and proprietary ability to produce a nearly limitless supply of individualized (autologous) vaccine for potentially every cancer patient, a vaccine created from the body's own dendritic cells pulsed with amplified messenger RNA (mRNA) from the patient's cancer (RNA-loaded DC vaccines).